News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Amplia.
RELATED STOCKHEAD STORIES
Health & Biotech
Check Up: Biotechs are getting crushed, but expert says we shouldn’t dismiss them
Health & Biotech
ASX Health Stocks: Alterity is set to launch Phase 2 clinical trial on Multiple System Atrophy
News
Market Highlights and 5 ASX Small Caps to watch on Thursday
Health & Biotech
Here’s how Immutep and other immunotherapy biotechs have changed cancer treatment
Health & Biotech
ASX Health Stocks: Cancer fighter Amplia will start Phase 2 trial after getting final ethics approval
News
Market Highlights and 5 ASX Small Caps to watch on Friday
Health & Biotech
ASX Health Stocks: Amplia Therapeutics gains momentum on pancreatic cancer drug
News
Market Highlights and 5 ASX Small Caps to watch on Thursday
Health & Biotech
ASX Health Stocks: Amplia eyes human trials for pancreatic cancer drug
News
10 at 10: These ASX stocks have struck the jackpot this morning
Health & Biotech
ASX Health Stocks: Amplia begins Phase 2 trial for pancreatic cancer, while Avecho commences Phase 1 of cannabis gel
Health & Biotech
ASX health stocks: HitIQ leaps 5% after deal to trial junior rugby players with concussion technology
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
Positive clinical data sends Amplia Therapeutics nearly 50 per cent up
News
ASX Small Cap Lunch Wrap: Who’s getting an extension today?
News
10 at 10: These ASX stocks have risen to the skies this morning
Experts
